Patents Examined by Zinna Northington
  • Patent number: 10494364
    Abstract: The invention relates to capthepsin K inhibitors and uses thereof, specifically relates to a class of compounds having the formula (I) which are used for treating or preventing cathepsin dependent diseases or conditions, specifically, wherein the cathepsin is capthepsin K. The compounds and compositions thereof can be used as bone resorption inhibitors for the treatment of associated diseases.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: December 3, 2019
    Assignees: SUNSHIN LAKE PHARMA CO., LTD, NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED
    Inventors: Xiaojun Wang, Pingjian Zhou, Chuanwen Yang, Changwei Huang, Shaohui Xiong, Yingjun Zhang, Jiancun Zhang
  • Patent number: 10494367
    Abstract: Provided herein are methods for antagonizing the action of an ?4-integrin to treat various pathophysiological conditions utilizing pharmaceutical compositions of compounds or pharmaceutically acceptable salts or stereoisomer(s) thereof of formula I where R1, R2, R3, R4, R5, X and R6 are as described herein.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: December 3, 2019
    Assignee: Aviara Pharmaceuticals, Inc.
    Inventors: Ronald J. Biediger, Michele A. Benish, Robert V. Market, Michael M. Savage, Brandon M. Young
  • Patent number: 10487079
    Abstract: The invention relates to novel heteroaryl carboxamides, processes for their preparation, and their use for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: November 26, 2019
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Martin Hendrix, Frank-Gerhard Böß, Christina Erb, Joachim Krüger, Christoph Methfessel, Rudy Schreiber, Welf-Burkhard Wiese, Joachim Luithle
  • Patent number: 10472327
    Abstract: 6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: November 12, 2019
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Susan M. Royalty, Jill Marie Sturdivant, Geoffrey Richard Heintzelman
  • Patent number: 10472325
    Abstract: Disclosed is a process for the synthesis of Pirfenidone (1) from 5-methyl-2(1H)-pyridinone and chlorobenzene in the presence of a catalytic system consisting of a copper salt and an organic ligand, in the presence of a base. The process exploits the high efficiency of the catalytic system consisting of copper(I) salt and an organic ligand in the presence of an inorganic base in the N-amidation reaction of chlorobenzene, a cheap reagent also usable as solvent in this case; reaction conditions at high temperatures, at atmosphere pressure or higher, produce a reaction with good yields.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: November 12, 2019
    Assignee: PROCOS S.p.A.
    Inventors: Matteo Mossotti, Alessandro Barozza, Jacopo Roletto, Paolo Paissoni
  • Patent number: 10466562
    Abstract: Protic-soluble electrochromic materials, ion-paired electrochromic materials including protic-soluble electrochromic materials, as well as electrochromic media and electrochromic devices incorporating such materials, are provided. The use of protic solvent mixtures, especially mixtures incorporating water, allows for the use of a wider variety of substrate materials. For example, plastics that may be soluble in organic aprotic solvent systems may be used in water-based devices.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: November 5, 2019
    Assignee: GENTEX CORPORATION
    Inventors: Kelvin L. Baumann, Rongguang Lin, Punam Giri, Sue F. Franz
  • Patent number: 10464918
    Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: November 5, 2019
    Assignee: CRINETICS PHARMACEUTICALS, INC.
    Inventors: Jayachandra P. Reddy, Mahmoud Mirmehrabi, Madhukar Kota, Uttam Dash
  • Patent number: 10450271
    Abstract: The invention relates to compounds, compositions, and methods that can inhibit the biosynthesis of mycotoxins.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: October 22, 2019
    Assignee: Board of Trustees of Michigan State University
    Inventors: Frances Trail, A. Daniel Jones
  • Patent number: 10442769
    Abstract: The present invention provides a novel processes for preparation of methyl 3-(benzyloxy)-5-(2,4-difluorobenzylcarbamoyl)-4-oxo-1-(2-oxoethyl)-1,4-dihydropyiridine-2-carboxylate using novel intermediates.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: October 15, 2019
    Assignee: Hetero Research Foundation
    Inventors: Bandi Parthasaradhi Reddy, Kura Rathnakar Reddy, Dsari Muralidhara Reddy, Mogili Narsingam, Bandi Vamsi Krishna
  • Patent number: 10442828
    Abstract: There are provided compounds of: wherein T, A, Q, Z, R4, R5a, R5b, n, r, Het1 and Rx have meanings given in the description, which compounds are useful in synthesizing compounds that have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: October 15, 2019
    Assignee: Topivert Pharma Limited
    Inventors: Matthew Colin Thor Fyfe, Stephen Malcolm Thom
  • Patent number: 10441565
    Abstract: Provided are a conjugate of memantine and arctigenin, and a pharmaceutical composition comprising the conjugate. The conjugate can treat diseases associated with A? or Tau protein pathways, such as Alzheimer's disease or Parkinson's disease.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: October 15, 2019
    Assignee: SHENZHEN QINGYAQIRUI BIO-TECH CO., LTD.
    Inventors: Haifeng Sun, Zhiyuan Zhu, Jun Liu, Wei Yan, Ding Zhang, Jing Yang
  • Patent number: 10428026
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: October 1, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Stephen John Atkinson, Helen Elizabeth Aylott, Anthony William James Cooper, Emmanuel Hubert Demont, Lee Andrew Harrison, Thomas George Christopher Hayhow, Matthew J. Lindon, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • Patent number: 10428043
    Abstract: Disclosed herein are reaction compositions comprising an oxidation catalyst, a solvent, and a substrate that is dissolved in the solvent. The oxidation catalyst comprises a metal ion complexed with an ?-keto acid and a tridentate N,N,O-ligand. Also disclosed herein are methods for oxidizing a C—H bond of a molecule, the methods comprising contacting the molecule with a metal complex comprising a metal ion complexed with a tridentate N,N,O-ligand in the presence of an ?-keto acid and a solvent. In some embodiments, the oxidation catalyst or metal complex is linked to a solid support.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: October 1, 2019
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: John Philip Caradonna, Paul Christopher Tarves, Joshua McNally, Lauren Gregor Tighe
  • Patent number: 10413536
    Abstract: 6-Alkynyl-pyridine of general formula (I) their use as SMAC mimetics, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: September 17, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Ulrich Reiser
  • Patent number: 10414762
    Abstract: The invention relates to novel amides of acetic and propionic acids, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning ability and memory.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: September 17, 2019
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Joachim Luithle, Frank-Gerhard Böβ, Christina Erb, Katrin Schnizler, Timo Flessner, Marja van Kampen, Christoph Methfessel
  • Patent number: 10414750
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: September 17, 2019
    Assignee: Celgene Quanticel Research, Inc.
    Inventors: Young K. Chen, Toufike Kanouni, Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal
  • Patent number: 10406152
    Abstract: The present disclosure provides acetate salts of buprenorphine, and its anhydrates, solvates, hydrates, and crystalline forms thereof, where the acetate salts of buprenorphine are essentially free of impurities. The disclosure further provides method of preparing the acetate salts, buprenorphine free base prepared from the acetate salts, other salts prepared from the free base, and pharmaceutical compositions thereof essentially free of impurities.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: September 10, 2019
    Assignee: RHODES TECHNOLOGIES
    Inventors: C. Frederick M. Huntley, Erik Wayne Kataisto, Helge Alfred Reisch, Archana Sharma
  • Patent number: 10399975
    Abstract: The present disclosure provides processes for the preparation of a compound of formula I: or a salt thereof, active on the receptor protein kinases c-Kit and/or c-Fms and/or Flt3. The disclosure also provides compounds and processes for the preparation of the compounds that are synthetic intermediates to the compound of formula I.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: September 3, 2019
    Assignees: Plexxikon Inc., Daiichi Sankyo Company, Limited
    Inventors: Prabha N. Ibrahim, Masayoshi Jin, Shinji Matsuura
  • Patent number: 10392384
    Abstract: The present invention relates to a novel process for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I) and recovering (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I) proceeding from (4R)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula ent-(I)
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: August 27, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Johannes Platzek, Kathrin Gottfried, Jens Assmann, Giulio Lolli
  • Patent number: 10392372
    Abstract: The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: August 27, 2019
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait